anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Insulin resistance (IR) is associated with coronary artery disease (CAD) severity. However, its underlying mechanisms are not fully understood. Therefore, our study aimed to explore the relationship between IR and coronary inflammation and investigate the synergistic and mediating effects of coronary inflammation on the association between IR and CAD severity.
METHODS: Consecutive patients with CAD who underwent coronary angiography and coronary computed tomography angiography between April 2018 and March 2023 were enrolled. The triglyceride-glucose index (TyG index) and peri-coronary adipose tissue (PCAT) attenuation around the proximal right coronary artery (RCA) were used to evaluate IR and coronary inflammation, respectively. The correlation between the TyG index and PCAT attenuation was analyzed using linear regression models. Logistic regression models were further used for investigating the correlation of the TyG index and PCAT attenuation with CAD severity. A mediation analysis assessed the correlation between IR and CAD severity mediated by coronary inflammation.
RESULTS: A total of 569 participants (mean age, 62 ± 11 years; 67.8% men) were included in the study. PCAT attenuation was positively associated with the TyG index (r = 0.166; P < 0.001). After adjusting for potential confounders, the per standard deviation increment in the TyG index was associated with a 1.791 Hounsfield unit (HU) increase (95% confidence interval [CI], 0.920-2.662 HU; P < 0.001) in the PCAT attenuation. In total, 382 (67.1%) patients had multivessel CAD. The patients in the high-TyG index/high PCAT attenuation group had approximately 3.2 times the odds of multivessel CAD compared with those in the low-TyG index/low PCAT attenuation group (odds ratio, 3.199; 95%CI, 1.826-5.607; P < 0.001). Mediation analysis indicated that PCAT attenuation mediated 31.66% of the correlation between the TyG index and multivessel CAD.
CONCLUSIONS: The TyG index positively correlated with PCAT attenuation in patients with CAD. The TyG index and PCAT attenuation showed a synergistic correlation with multivessel CAD. Furthermore, PCAT attenuation partially mediated the relationship between the TyG index and CAD severity. Controlling inflammation in patients with high IR and coronary inflammation may provide additional benefits.
PURPOSE:To obtain the titled material having a small min. optical density and capable of easily handling at a yellow light by incorporating a specific compd. to an emulsion layer or a hydrophilic colloid layer adjacent to said layer. CONSTITUTION:The emulsion layer of the titled material is composed of the direct positive type silver halide emulsion which is previously fogged. The silver halide contains >=70% silver chloride. The emulsion layer or the hydrophilic colloid layer adjacent to said layer contains >=1 kinds of the compd. shown by the formula. In the formula, Z1 is a nonmetallic atom group necessary to forming a nitrogen-contg. heterocyclic ring, T is halogen atom or alkyl, alkenyl, cyano or hydroxy group, etc., (q) is 1, 2 or 3, (r) is 0, 1 or 2. Thus, the titled material having the low min. optical density and capable of easily handling at a light room which is shined the yellow light or cut the UV ray, is obtd.
Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.
The investigators conduct a randomized controlled trial to evaluate the (cost-)effectiveness of ABFT compared to Treatment As Usual (TAU) on suicidality, as delivered in daily practice. The hypothesis is that, compared to TAU, ABFT will lead to a stronger reduction of suicidal ideation and suicidal behavior, and will be more cost-effective, will improve family functioning and young adult attachment, and that this effect will hold at follow-up. The primary objective is change in suicidality, that is, suicidal ideation, attempts and suicide as assessed by the Suicidal Ideation Questionnaire Junior (SIQ-JR), and as reported by therapists during treatment. Secondary objectives are cost-effectiveness, process, working alliance and adherence during treatment, and change in young adult depressive symptoms, family functioning, and young adult attachment.

Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks. Treatment as usual (TAU): Participants in both arms will receive TAU, in the experimental condition ABFT will be delivered as an add-on. Most treatment centres' clinical practices rely heavily on the use of antidepressants and/or CBT or DBT. All regular interventions are allowed in TAU, except for systemic family therapy of more than 4 sessions in total. Parents are allowed to be involved in the treatment, which is part of treatment as usual, and can comprise for instance psycho-education or parental support or skill training.
Of the 1539 subjects with AD exposed to DUPIXENT in a dose-ranging study and placebo-controlled trials, 70 subjects were 65 years or older. Clinical trials of DUPIXENT in AD did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects [see Clinical Pharmacology (12.3)].

Of the 1977 subjects with asthma exposed to DUPIXENT, a total of 240 subjects were 65 years or older. Efficacy and safety in this age group was similar to the overall study population.

Of the 440 subjects with CRSwNP exposed to DUPIXENT, a total of 79 subjects were 65 years or older. Efficacy and safety in this age group were similar to the overall study population.

Clinical studies of DUPIXENT in EoE did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger adult subjects.

Of the 152 subjects with PN exposed to DUPIXENT, a total of 37 were 65 years or older including 8 subjects 75 years or older. Clinical trials did not include a sufficient number of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

Of the 1874 subjects with COPD randomized in clinical trials of DUPIXENT, a total of 1072 were 65 years or older, while 244 subjects were 75 years or older. No overall differences in safety or effectiveness of DUPIXENT have been observed between subjects 65 years of age and older and younger adult subjects.
Technology is described for storing and reading a data file using a token encoded in a printed optical code. The method can include receiving the data file over a computer network from a client device. The data file can be sent to be stored in a data store of virtualized data storage accessible via the internet. A token may be received from the data store and the token can be used to access the data file. The data file is returned from the data store when the token is later received from a client device. The token is encoded into an optical code. The optical code can be sent to the client device, where the client device has access to a printer to print the optical code with the token encoded. Any electronic copy of the token can be destroyed.
Knee osteoarthritis, caused by non-uniform settlement of medial and lateral tibial plateau, was not uncommon in clinic. Medial stenosis was the most type of the disease. The symptoms included knee pain during walking and varus deformity of lower limbs. Total knee arthroplasty and tibial osteotomy were two common conventional treatment of the knee osteoarthritis, which were not minimally invasive and bring great financial burden to patients' family. The investigators planned to recruit 150 patients of knee osteoarthritis into this study, which were randomly divided into two groups (study group and control group). For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line. However, total knee arthroplasty was conducted for the patients of control group. The patients were followed up and the clinical outcomes were compared in this study.
Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 1 neonates will receive low dose intravenous caffeine citrate (5 mg/kg).
The invention relates to an anti-IDH 1R132H antibody, a preparation method and application thereof. The antibody or functional derivative thereof specifically recognizes an epitope of IDH1R132H, the monoclonal antibody having: (1) SEQ ID NO: 2. 6 or 10, or a conservative variant thereof; and (2) SEQ ID NO: 4. 8 or 12, or a conservative variant thereof. The invention also relates to a nucleic acid molecule for coding the antibody, a construction vector, an expression system, a corresponding humanized antibody, a preparation method, application and a pharmaceutical composition. The antibody of the invention has immunospecificity on human I type human isocitrate dehydrogenase (IDHI1) R132H, can specifically recognize the mutation site of IDH1R132H related to malignant diseases and can be combined with the mutation site specifically to diagnose and treat diseases which play a pathogenic role after IDH1R132H mutation, such as glioma, leukemia and the like.
This arm includes two-thirds of enrollees and focuses on both acute and chronic effects of exercise. Qualifying participants with heart failure randomized to this arm will undergo a 40 minute bout of moderate intensity exercise on a date prior to beginning in cardiac rehabilitation. Blood samples will be collected before and after the acute bout at 10, 30, and 210 minutes after exercise. Participants will then go to cardiac rehabilitation for a 12 week period. A single blood sample will be obtained at 6 weeks. The participants will return after the 12 weeks of cardiac rehabilitation for a second bout of acute exercise and blood sampling identical to the first. Finally, 12 weeks after completion of cardiac rehab, patients will return for another single blood sample.
Myocardial ischemia-reperfusion injury (MIRI) is a severe damage inflicted on the ischemic myocardium when blood flow is restored, and it commonly occurs in a wide range of cardiovascular diseases. Presently, no effective clinical treatment exists for MIRI. Accumulating evidence indicates that insulin-like growth factor-1 (IGF-1) plays a role in the intricate chain of cardiovascular events, in addition to its well-recognized growth-promoting and metabolic effects. IGF-1, a member of the insulin family, exhibits a broad spectrum of protective effects against ischemia/reperfusion injury in various tissues, especially the myocardium. In particular, earlier research has demonstrated that IGF-1 reduces cellular oxidative stress, improves mitochondrial function, interacts with noncoding RNAs, and activates cardiac downstream protective genes and protective signaling channels. This review aimed to summarize the role of IGF-1 in MIRI and elucidate its related mechanisms of action. In addition, IGF-1-related interventions for MIRI, such as ischemic preconditioning and post-conditioning, were discussed. The purpose of this review was to provide evidence supporting the activation of IGF-1 in MIRI and advocate its use as a therapeutic target.
The main objective of this current study is to explore the effectiveness of specific benefits of key components of the Night Time Care Activities Programme- NightCAP. Particularly elements of sleep hygiene and personalised night-time care planning. There may also be additional benefit in combining NightCAP elements with pharmacological review protocol to enable management of all major contributing factors in sleep disturbance.

This cluster-randomised trial will be delivered in 24 UK care homes. Participants will be individuals living with dementia and experiencing sleep disturbance, as well as staff who care for them. Homes will be randomly allocated to one of two arms: optimised usual care or the intervention arm. All homes will receive an optimised person-centred care module. The NightCAP intervention programme consists of three key elements: (i) personalised night-time care planning (supported staff training and implementation); (ii) structured sleep hygiene (staff training); and (iii) hypnotic drug review protocol (GP fact sheet and staff training). The primary outcome will be sleep disturbance at the end of the intervention. Secondary outcomes will be hypnotic drug use, quality of life, resident falls, job satisfaction, burden and coping in care staff, and cost effectiveness.
The present invention relates to a hair shampoo composition containing (A) an amphipathic amide lipid, and (B), from 5 to 30 wt. % of sulfate surfactants which are each represented by the formula: R—O—(C 2 H 4 O) a —SO 3 M (wherein, R represents a C 8-18  alkyl or alkenyl group, a stands for 0 or a positive integer, and M represents an alkali metal, alkaline earth metal, or the like); are made of from 30 to 45 wt. % of a sulfate exhibiting a=0, from 18 to 27 wt. % of another sulfate exhibiting a=1, from 10 to 20 wt. % of a further sulfate exhibiting a=2, and the balance of further sulfates exhibiting a=3 or greater; and contain the sulfates exhibiting a=0 to 2 in an amount of 70 wt. % or greater based on the total sulfates. The hair shampoo composition of the present invention is able to for example have good foaming property, provide foam with good lubrication upon shampooing, have smooth feel upon rinsing, impart a pleasant feel such as gloss, manageability, resilience and strength to the hair after shampooing, and protect the hair from physical or chemical stimulation to make it resistant to damage.
PURPOSE: To obtain a composition accelerating quick passage of a substance usually incapable of passing through a blood-brain barrier from the blood to the brain by including extremely pure sugar, amino sugar or amino acid. CONSTITUTION: This composition contains an extremely pure (97-99% of crystal purity) sugar, e.g. mesoerythritol, xylitol, D(+)galactose, D(+)lactose, etc., or amino sugar, e.g. D(+)glucosamine, D-mannosamine, D-galactosamine and amino acid (e.g. glutamine, lysine, arginine or asparagine). A combination of the sugar with the amino acid is effective for overcoming an action of alcoholism and attaining of quick recovery of a motional function, and a combination of the sugar and β-carotene and/or xanthophyll is effective for accelerating hair growth and overcoming a baldness.
The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing neurological disorders are disclosed.
The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
Patients who underwent presbyopic correction with bilateral trifocal intraocular lenses implantation are supposed to have sufficient uncorrected vision capacity for activities of daily living (ADLs) that require near vision acuity (NV), (ie. book reading). However, it is known that light intensity and temperature has a great impact on near vision capacity. Primary objective of this study is to identify the optimal task lighting conditions (in terms of light intensity and temperature) for ADLs that demand near vision acuity for a sample of patients who underwent presbyopic correction with bilateral trifocal intraocular lenses implantation. The following light intensities will be evaluated: 25, 50, and 75 foot candles. Moreover, the following light temperatures will be evaluated: 3000, 4000, and 6000 Kelvins.
This patent application deals with the revealing of the effectiveness of Balanites aegyptiaca bark aqueous extract in treatment of both experimental obstructive jaundice in rats and infective hepatitis in humans. It also reveals the magnitude of safety of the aqueous extract. Intraperitoneal administration of the aqueous extract (15-60 % w/v) to biliary ducts-ligated rats (i.e. experimentally-induced obstructive jaundice) for 3 days in doses of 1.2-4.8 g bark/kg/day (equivalent to 4.91-29.64 mg of freeze-dried aqueous extract/kg) significantly reduced the blood bilirubin concentration by 22-45.9 %. The LD50 values in mice were 33 g bark (= 1320 mg of freeze-dried aqueous extract (F.D.E.) per kg intraperitoneally and 136 g bark (= 5440 mg of freeze-dried aqueous extract) per kg orally. Oral treatment of rats with 65-1625 mg F.D.E./kg/day for 21 days did not produce any significant changes in blood haematological parameters, various blood constituents, locomotor activity, behaviour or respiration as it did not affect any of the vital organs such as the heart, lungs, kidney, spleen, liver and gastrointestinal tract. There was no teratogenicity in rats. Similarly, feeding chicks with the powdered bark mixed in the normal daily food at a level of 2 % or 10 % did not induce any significant changes in blood cellular elements and constituents. Treatment of 242 patients with infective hepatitis with the aqueous extract (15 % w/v) at doses of 30 ml 3 times daily for 3 days resulted in complete treatment of 82 % of the patients with no bile in urine on the 5th day, 11 % of the patients improved in 10 days, 6 % in 2 weeks and 1 % death. The treatment was very well tolerated by the patients without any side effects or complications.
The primary outcome is change in urinary NGAL expression with conversion from IR tacrolimus to tacrolimus XR. In aim 1, changes in urinary biomarkers of tubular injury at 4 weeks after conversion to tacrolimus XR with stable trough levels will be assessed. These changes will be assessed by CYP3A5 expressor category that will be determined by genotyping of a single gene for variants. The changes in GFR using the creatinine-cystatin C CKD-EPI equation will be assessed. In aim 2, the rate of rejection as defined as treated rejection within the last 30 days for any grade \> 1R or AMR or acute graft dysfunction (LV ejection fraction drop \> 10%) will be looked. The cardiac allograft vasculopathy based on coronary angiography +/- IVUS and right heart catheterization hemodynamics at baseline and 1 year post conversion will also be evaluated. In addition to changes in cardiac function, the changes in blood pressure, serum glucose, and cholesterol in the first year after conversion will be assessed.
This is a single-center, open-label Phase Ib clinical trial. In this trial, adult subjects with pancreatic ductal adenocarcinoma who have completed resection of the primary tumor and who have not undergone preoperative chemotherapy will be enrolled in the study. Eligible enrolled patients all will undergo tumor resection and all receive adjuvant chemotherapy prior to preparation of the personalized neoantigen vaccine. After the chemotherapy finish, subsequently patients will receive a priming immunization with five doses of the personalized neoantigen vaccine over one month and a boosting immunization with two doses three months later. This clinical trial will examine the safety and effect of the personalized neoantigen vaccine when given at several different time points and will examine the participant's peripheral blood cells for signs that the vaccine induces immunologic responses. Finally we will establish the typical flow to assess efficiency and safety of vaccines according to the different reactivity of patients, as a result, to explore the most suitable practical approaches for applying personalized pancreatic tumor vaccines.
NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
The clinical impact of therapy-related acute leukemias is increasing with the extension of cancer-related survival; however, the origins remain largely unknown. Acute erythroleukemia (AEL), a rare unfavorable type of myeloid neoplasia, may also develop secondary to cytotoxic therapy. The disorder is featured by specific genetic alterations, most importantly multi-allelic mutations of the TP53 gene. While AEL might appear as a part of the therapy-related MDS/AML, spectrum information regarding the genetic complexity and progression is largely missing. We present two AEL cases arising after cytotoxic therapy and melphalan-based myeloablation/autologous peripheral stem cell transplantation due to multiple myeloma (MM). As stated, multiple pathogenic TP53 variants were present unrelated to preexisting MM, in parallel with uninvolved/wild-type hemopoiesis. Potential mechanisms of leukemic transformation are discussed, which include (1) preexisting preneoplastic hemopoietic stem cells (HSC) serving as the common origin for both MM and AEL, (2) the generation and intramedullary survival of p53-deficient post-chemotherapy HSCs, (3) reinoculation of mobilized autologous TP53 mutated HSCs, and (4) melphalan treatment-related late-onset myelodysplasia/leukemia with newly acquired TP53 mutations.